A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
The purpose of this study is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum parathyroid hormone (PTH) levels by > 30% from baseline among patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) who require management with hemodialysis.
Inclusion Criteria:
Exclusion Criteria:
Praha 4 - Nusle, 140 00, Czechia
Nikaia, Piraeus, 18454, Greece
San Giovanni Rotondo FG, 71013, Italy
Papatoetoe, Auckland, 2025, New Zealand
Takapuna, Auckland City, 0622, New Zealand
Forte Da Casa, 2625-437, Portugal
Mitishi, 141009, Russia